{
    "relation": [
        [
            "Arms",
            "Experimental: HBV-5 Group neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)",
            "Experimental: HBV-6 Group neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)",
            "Experimental: HBV-3 Group neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)",
            "Experimental: HBV-4 Group neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)",
            "Experimental: HBV-2 Group neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)",
            "Experimental: HBV-1 Group neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)"
        ],
        [
            "Assigned Interventions",
            "Biological: Engerix\u2122-B In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.",
            "Biological: Engerix\u2122-B In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.",
            "Biological: Engerix\u2122-B In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.",
            "Biological: Engerix\u2122-B In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.",
            "Biological: Engerix\u2122-B In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.",
            "Biological: Engerix\u2122-B In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60."
        ]
    ],
    "pageTitle": "Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/NCT00240500?rslt=With&rank=9",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986615.83/warc/CC-MAIN-20150728002306-00217-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 843997611,
    "recordOffset": 843981666,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{467=The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.}",
    "textBeforeTable": "November 2007 (Final data collection date for primary outcome measure) Primary Completion Date: November 2007 Study Completion Date: October 2003 Study Start Date: 109 Enrollment: Clinical Review for Hepatitis B Infection Status [\u00a0Time\u00a0Frame:\u00a0Over the entire 4 year follow up period (17 - 20 years)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Prevalence of Serological Markers for Hepatitis B Infection [\u00a0Time\u00a0Frame:\u00a0Years 17, 18, 19 and 20.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations [\u00a0Time\u00a0Frame:\u00a0Years 17, 18, 19 and 20.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Primary Outcome Measures: Further study details as provided by GlaxoSmithKline: U.S. FDA Resources Hepatitis\u00a0B Hepatitis\u00a0A Hepatitis MedlinePlus related topics: Resource",
    "textAfterTable": "Detailed Description: The primary study was designed to evaluate the immunogenicity and protective efficacy of hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group. The present study is carried out to evaluate the anti-HBs persistence 16-20 years after the first vaccine dose and to further investigate the prevalence and incidence of other hepatitis B markers and the clinical significance of these at all time points from Year 16-20. No additional subjects will be recruited during this long-term follow-up study and no vaccine will be administered. \u00a0 Eligibility Ages Eligible for Study: \u00a0 16 Years to 20 Years Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 Yes Criteria Inclusion Criteria: Subjects who had received at least one dose of the study vaccine in the primary study (103860/064) Written informed consent obtained from each subject before each blood sampling visit",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}